Kokarboksilaza-Ellara

General characteristics. Structure:

Active ingredient - cocarboxylase гидрохлоид 50 mg.

Excipient - sodium a carbonate of 8 mg.

Pharmacological properties:

Pharmacodynamics. Cocarboxylase — a coenzyme of thiamin (B1 vitamin), in an organism is phosphorylated with education mono - di - and trifosforny ethers, is a part of the enzymes catalyzing a carboxylation and decarboxylation of alpha ketonic acids. Exogenous B1 vitamin (thiamin) for participation in these processes has to be metabolized by phosphorylation in cocarboxylase — a ready form of a coenzyme. It is necessary to consider that properties of cocarboxylase are only partially adequate to that at thiamin; cocarboxylase is not used for prevention and treatment hypo - and B1 avitaminosis.

Indications to use:

Cocarboxylase is appointed in complex therapy of a liver and renal failure, a diabetic prekoma and coma, diabetic ketoacidosis, chronic heart failure and disturbances of a cordial rhythm, peripheral neuritis.

To children drug is appointed according to the same indications. At newborns drug is used also in complex therapy of the states connected with a hypoxia and acidosis including asphyxia of newborns, hypoxemic encephalopathy, a circulatory unefficiency, pneumonia, sepsis, etc.

Route of administration and doses:

Intramusculary or intravenously (struyno or kapelno).

Ampoule contents (25 or 50 mg) just before use are dissolved in 2 ml of water for injections. For in/in jet introductions the volume of solution should be brought to 10-20 ml, for drop introduction - to 200-400 ml (adding 0.9% NaCl solution or solution of a dextrose).

At heart diseases enter on 100-200 mg/days within 15-30 days.

At a diabetes mellitus (ketoacidosis, a coma) the daily dose makes 100 mg.

At an acute renal and liver failure - intravenously struyno, on 100-150 mg 3 times a day or kapelno (for 5% dextrose solution), on 100-150 mg/days.

At peripheral neuritis - intramusculary, in a dose of 50-100 mg/days within 1-1.5 months.

To children - intramusculary, intravenously (kapelno or struyno): depending on weight and clinical symptomatology - 25-50 mg/days. A course of treatment - from 3-7 to 15 days. The newborn enter intravenously slowly - 10 mg/kg of 1 times a day.

Features of use:

Are not specified.

Side effects:

Allergic reactions (urticaria, itch), at introduction in oil - a hyperemia, an itch, hypostasis (in the place of an injection).

Interaction with other medicines:

Strengthens cardiotonic effect of cardiac glycosides and improves their portability.

Contraindications:

Hypersensitivity to drug.

Overdose:

Today data on overdose by drug are absent.

Storage conditions:

To store in the place protected from light at a temperature not above 10 °C.

To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 50 mg of drug in ampoules. 5 ampoules with drug in a blister strip packaging from a film polyvinyl chloride.

1 or 2 blister strip packagings together with the instruction about use and the scarificator ampoule place in a pack cardboard.

1 blister strip packaging with drug complete with solvent (water for injections on 2 ml) together with the instruction in a pack cardboard.

On 10 ampoules with drug in blister strip packagings together with the application instruction and the scarificator ampoule in a pack from a cardboard with a corrugated insert.

When using ampoules with a point or a ring of a break the scarificator ampoule is not put.